Fulcrum Therapeutics Inc
Follow $FULC
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $FULC by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is FULC moving today?
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
FULC overview
Related filings and maps
Congress activity in FULC
No receipt-qualified filings found.
FULC contract awards, year to date.
Public federal awards linked to this ticker.
FULC lobbying filings, year to date.
Registered lobbying filings matched to Fulcrum Therapeutics Inc.
THE MCMANUS GROUP
THE MCMANUS GROUP
THE MCMANUS GROUP